Dr. Shulman on the CALGB 40101 Trial

Lawrence N. Shulman, MD
Published Online: Wednesday, November 13, 2013
Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses the results of the CALGB 40101 trial.

The trial, which compared the efficacy of adjuvant cyclophosphamide (AC) and doxorubicin versus paclitaxel, showed that paclitaxel is not equivalent to the AC combination, Shulman says.

Shulman says all statistical analyses showed that the AC combination is still the most effective treatment and that combination chemotherapy is essential. Unfortunately, Shulman says, AC is more toxic. Although the AC arm of the study had more occurrences of leukemia and cardiac death, it is still a better regimen overall.

Online CME Activities
Free CME from PER
Advances in ImmunoOncology: Intralesional Oncolytic Immunotherapy in Melanoma
Updates in the Treatment of Lung Cancer
10th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® Medical Crossfire®
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
More Reading
$auto_registration$